Biblio

Found 10 results
Filters: Keyword is Opioid-Related Disorders  [Clear All Filters]
2024
Chapman SA, Fraimow-Wong L, Phoenix BJ, Tierney M, Spetz J. Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain. J Subst Use Addict Treat. 2024 ;157:209215.
2023
Jones KFitzgerald, Jacob MO'Reilly, Spetz J, Hailer L, Tierney M. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach. J Nurs Scholarsh. 2023 ;55(3):655-664.
Cooke A, Castellanos S, Enriquez C, Olsen P, Miaskowski C, Kushel M, Knight KRay. Telehealth for management of chronic non-cancer pain and opioid use disorder in safety net primary care. BMC Health Serv Res. 2023 ;23(1):325.
2022
Andraka-Christou B, Gordon AJ, Spetz J, Totaram R, Golan M, Randall-Kosich O, Harrison J, Calder S, Kertesz SG, Stein BD. Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing. J Subst Abuse Treat. 2022 ;138:108715.
Spetz J, Hailer L, Gay C, Tierney M, Schmidt LA, Phoenix B, Chapman SA. Buprenorphine Treatment: Advanced Practice Nurses Add Capacity. Health Aff (Millwood). 2022 ;41(9):1231-1237.
Spetz J, Hailer L, Gay C, Tierney M, Schmidt L, Phoenix B, Chapman S. Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements. JAMA Netw Open. 2022 ;5(5):e225996.
Shin SS, LaForge K, Stack E, Pope J, Leichtling G, Larsen JE, Leahy JM, Seaman A, Hoover D, Chisholm L, et al. "It wasn't here, and now it is. It's everywhere": fentanyl's rising presence in Oregon's drug supply. Harm Reduct J. 2022 ;19(1):76.
Beliveau CM, McMahan VM, Arenander J, Angst MS, Kushel M, Torres A, Santos G-M, Coffin PO. Stimulant use for self-management of pain among safety-net patients with chronic non-cancer pain. Subst Abus. 2022 ;43(1):179-186.
2021
Chu CE, Law L, Zuniga K, Lin TKuo, Tsourounis C, Rodriguez-Monguio R, Lazar A, Washington SL, Cooperberg MR, Greene KL, et al. Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. Urology. 2021 ;149:168-173.
2020
Gibson CJ, Grasso J, Li Y, Purcell N, Tighe J, Zamora K, Nicosia F, Seal KH. An Integrated Pain Team Model: Impact on Pain-Related Outcomes and Opioid Misuse in Patients with Chronic Pain. Pain Med. 2020 ;21(9):1977-1984.